Pharmaceutical Solid Dosage Contract Manufacturing Market May Set New Growth Story | BioPharma Solutions, Pillar5 Pharma, Emergent BioSolutions, Haupt Pharma
iCrowd Newswire
12 May 2021, 21:05 GMT+10
The latest analysis released by HTF MI on COVID-19 Outbreak-Global Pharmaceutical Solid Dosage Contract Manufacturing Market Outlook 2021 Survey results sheds light on how investment and competitive landscape is impacted due to significant changes in the COVID-19 Outbreak- Pharmaceutical Solid Dosage Contract Manufacturing Industry. The research coverage includes analysis on companies such as Covance, Althea Technologies, Fresenius Kabi, Mikart, Emergent BioSolutions, Catalent Pharma Solutions, BioPharma Solutions, Abbott Laboratories, Associates of Cape Cod, Pillar5 Pharma, Haupt Pharma, Lyophilization Technology, DPT Laboratories, Cytovance Biologics, Halo Pharmaceutical, Alkermes & Jubilant Life Sciences Limited etc. It is expected that the healthcare and life sciences industry
Representational Image
During the second wave of COVID-19, stocks of pharmaceutical, oxygen and other companies involved in tackling COVID-19 have been in focus. But today, there may be some pharmaceutical stocks that may draw more attention of investors.
Given is the list of stocks:
Cipla and Jubilant Life Sciences: Both these stocks may buzz when the market opens today. This is because the Karnataka government on Tuesday served notices to pharmaceutical majors Cipla and Jubilant warning them of legal proceedings for not supplying adequate quantities of Remdesivir injection bottles as directed by the Government of India. In a notice to the pharmaceutical companies, the Principal Secretary in the Revenue department N Manjunatha Prasad said they were ordered to deliver 62,000 vials of Remdesivir injection, but they supplied very less consignment. Cipla and Jubilant were ordered to supply 30,000 and 32,000 vials respectively by May 9. However, they supplied only 10,840 and 17,601 v
Jubilant Pharmova rose 1.70% to Rs 849.70 after the company said its subsidiary, Jubilant Pharma, received a favorable and unanimous judgment from the US Court of Appeals.Jubilant Pharma, a subsidiary of Jubilant Pharmova, announced that it has received a favorable and unanimous judgment from the United States Court of Appeals summarily affirming Jubilant s earlier favorable rulings from the US Patent Office ( PTAB ) and the US International Trade Commission ( ITC ). These two rulings by the Appellate Court deny the appeals filed by Bracco Diagnostics, Inc.
Jubilant successfully challenged Bracco s patent infringement claims in an Inter Parties Review (IPR) proceeding before the U.S. Patent Office as well as in a separate proceeding in the ITC. In both instances, Jubilant was successful.
Express News Service
CHENNAI: At Government Tiruvannamalai Hospital, in Covid-19 wards choking with suffering, an insidious business was afoot. Helming it was Ramesh , a hospital helper, tasked with administering Remdesivir injection to Covid-19 patients. Ramesh, however, was not oblivious of the black-market price of the drug.
So, when a doctor tells him to administer Remdesivir to a patient, he would make his own ‘observation’ to check whether the patient would live or not. If his ‘prognosis’ was negative, which they often were, Ramesh kept the vial for himself, and lied to the doctor that the injection had been given.
This ugly business, however, came undone when Mohammed Imran Khan, a 25-year-old Tambaram doctor who had purchased the vials from Ramesh for sale in the black market, was busted. Superintendent of Police (Civil Supplies CID) S Santhi, whose team arrested the suspects, said Ramesh had stolen vials after vials this way and sold them to Khan.